IBRX
Immunitybio Inc
8.60$
+0.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 49.7% | 58.3% | 48.8% | 54.7% | 44.8% | 48.2% | 35.9% | 51.8% | 63.5% | 62.7% | 70.0% | 69.8% | |
| 41.2% | 52.6% | 33.2% | 29.3% | 30.7% | 37.5% | 20.0% | 34.2% | 11.6% | 17.6% | 31.7% | 12.0% | |
| 43.9% | 52.8% | 42.6% | 49.1% | 35.8% | 39.1% | 20.3% | 38.2% | 49.7% | 48.4% | 58.9% | 56.9% | |
| 0.5% | 0.6% | 0.5% | 0.5% | 1.3% | 0.7% | 5.7% | 5.6% | 6.5% | 8.5% | 6.7% | 8.5% | |
| 3.8% | – | – | 0.4% | 0.5% | 2.2% | 2.8% | 1.7% | 1.3% | 0.2% | 0.1% | 0.3% | |
| – | – | – | – | 0.2% | 0.2% | 0.3% | 0.2% | 0.2% | 0.2% | 0.1% | 1.9% | |
| 4.3% | 3.4% | 4.1% | 3.6% | 4.3% | 3.9% | 4.8% | 3.5% | 2.6% | 2.6% | 1.9% | 1.9% | |
| 195.0% | 216.2% | 272.5% | 257.0% | 304.1% | 227.5% | 294.4% | 241.7% | 200.9% | 199.5% | 234.4% | 266.4% | |
| 20.9% | 11.6% | 13.4% | 14.0% | 16.7% | 14.3% | 16.2% | 12.6% | 11.0% | 12.3% | 10.5% | 12.2% | |
| 1.0% | 1.0% | 1.5% | 1.4% | 1.9% | 1.9% | 2.5% | 1.8% | 1.4% | 1.9% | 1.3% | 1.2% | |
| 4.6% | 1.8% | 3.5% | 4.6% | 2.7% | 1.8% | 4.4% | 1.8% | 1.1% | 1.4% | 1.7% | 1.9% | |
| 155.8% | 135.1% | 171.5% | 155.9% | 191.8% | 120.6% | 159.9% | 122.4% | 96.5% | 95.1% | 104.9% | 123.2% | |
| -95.2% | -116.4% | -172.7% | -157.2% | -204.4% | -127.7% | -194.7% | -142.0% | -101.0% | -99.5% | -134.5% | -166.5% | |
| -630.9% | -587.1% | -772.6% | -727.0% | -909.6% | -881.4% | -1,153.8% | -894.7% | -706.1% | -742.5% | -674.2% | -730.3% | |
| 115.3% | 117.1% | 167.9% | 154.6% | 191.4% | 191.8% | 280.9% | 220.9% | 182.4% | 197.2% | 158.8% | 167.1% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.